SOLA Biosciences
Pre-clinicalSOLA Biosciences develops JUMP70 platform therapies targeting protein misfolding in ALS, Parkinson’s, and other conformational diseases.
Founded
2018
Focus
RNA & Gene Therapy
About
SOLA Biosciences develops JUMP70 platform therapies targeting protein misfolding in ALS, Parkinson’s, and other conformational diseases.
Funding History
1Total raised: $5M
Seed$5MUndisclosedJun 15, 2022
Company Info
TypePrivate
Founded2018
LocationSan Diego, United States
StagePre-clinical
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile